Valuation: CorMedix Inc.

Capitalization 62Cr 53Cr 48Cr 46Cr 85Cr 5.87TCr 86Cr 573Cr 223.37Cr 2.82TCr 233.08Cr 228.18Cr 9.73TCr P/E ratio 2026 *
15.5x
P/E ratio 2027 * 37.5x
Enterprise value 62Cr 53Cr 48Cr 46Cr 85Cr 5.87TCr 86Cr 573Cr 223.37Cr 2.82TCr 233.08Cr 228.18Cr 9.73TCr EV / Sales 2026 *
2.02x
EV / Sales 2027 * 2.2x
Free-Float
99.03%
Yield 2026 *
-
Yield 2027 * -
1 week+1.67%
Current month+4.35%
1 month+9.54%
3 months+2.99%
6 months-26.39%
Current year-31.90%
1 week 7.62
Extreme 7.6201
8.15
1 month 7.05
Extreme 7.05
8.15
Current year 6.12
Extreme 6.125
12.29
1 year 6.12
Extreme 6.125
17.43
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 10/05/2022
Director of Finance/CFO 54 29/08/2025
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 67 06/08/2015
Chairman 81 03/08/2017
Director/Board Member 70 16/08/2011
Change 5d. change 1-year change 3-years change Capi.($)
0.00%+1.67%-34.16%+50.86% 62Cr
-1.66%+2.54%-6.93%-30.06% 5.78TCr
-2.82%-2.84%+6.23%-22.72% 777.45Cr
-1.64%+0.25%-5.33%+111.76% 759.66Cr
-0.20%-0.50%+1.53%+41.19% 532.71Cr
-1.59%-5.46%-21.13%+57.86% 440.11Cr
-2.87%-0.96%+1.68%-22.06% 318.25Cr
-1.43%+7.69%+63.38%+40.07% 299.08Cr
+1.28%+1.17%+22.28%+10.99% 254.6Cr
-2.34%-0.06%+79.68%+30.58% 203.87Cr
Average -1.33%+1.53%+10.72%+26.85% 942.29Cr
Weighted average by Cap. -1.63%+1.65%-0.89%-4.44%

Financials

2026 *2027 *
Net sales 31Cr 26Cr 24Cr 23Cr 42Cr 2.91TCr 43Cr 284.28Cr 110.82Cr 1.4TCr 115.64Cr 113.2Cr 4.83TCr 28Cr 24Cr 22Cr 21Cr 39Cr 2.67TCr 39Cr 260.47Cr 101.54Cr 1.28TCr 105.95Cr 103.72Cr 4.42TCr
Net income 5.23Cr 4.45Cr 4.07Cr 3.84Cr 7.17Cr 494.34Cr 7.23Cr 48Cr 19Cr 237.45Cr 20Cr 19Cr 819.78Cr 3.04Cr 2.58Cr 2.36Cr 2.23Cr 4.15Cr 286.64Cr 4.19Cr 28Cr 11Cr 137.68Cr 11Cr 11Cr 475.34Cr
Net Debt - -
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Employees
191
Date Price Change Volume
08/26/08 7.920 $ 0.00% 8,58,922
07/26/07 7.920 $ -1.61% 8,93,174
06/26/06 8.050 $ +4.14% 11,64,884
05/26/05 7.730 $ -2.15% 8,50,281
04/26/04 7.900 $ +1.41% 11,00,568
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
7.920USD
Average target price
15.00USD
Spread / Average Target
+89.39%

Quarterly revenue - Rate of surprise